ArticleMolecular biology reports2026
Effects of stattic and vinblastine on apoptosis and fatty acid profile in A549 lung cancer cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeNon-small cell lung cancer (NSCLC) is among the most lethal cancers globally, partly due to dysregulated STAT3 signaling, which is related to tumor growth. Combination strategies involving STAT3 inhibitors with chemotherapeutic agents may improve therapeutic efficacy. Therefore, the current study assessed the effects of Stattic (a STAT3 inhibitor) in combination with vinblastine (a microtubule-destabilizing agent) against A549 lung cancer cells.
methodsThe antiproliferative effect was examined using MTT assay, apoptosis by Annexin V-FITC/PI and DAPI staining, cell cycle distribution by flow cytometry, and cell migration by wound-healing assay. Molecular changes in apoptosis-related genes were evaluated by qRT-PCR, and alterations in fatty acid profiles were analyzed via gas-liquid chromatography.
resultsThe IC₅₀ values for vinblastine and Stattic were 11.3 nM and 1.8 µM, respectively. Co-treatment of Stattic with vinblastine significantly inhibited cell migration, increased the percentage of apoptotic cells, elevated the mRNA expression of the pro-apoptotic gene Bak, and reduced the expression of anti-apoptotic genes Bcl-2 and Mcl-1. In addition, vinblastine treatment elevated saturated fatty acid levels, while Stattic increased monounsaturated fatty acid levels; their combination produced an intermediate lipid profile, indicating treatment-associated changes in cellular fatty acid composition.
conclusionThese findings suggest that the vinblastine-Stattic combination enhances anticancer activity in A549 cells and warrants further mechanistic and in vivo studies.
Indexed as
Identifiers
42474554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.